BCOP Exam Q-Bank - Sample Questions
The sample questions below were taken directly from our BCOP Q-Bank & Flashcard Database. They represent 470 other practice test questions you will encounter with the use of our BCOP Q-Bank. We believe our BCOP practice test questions and flashcards system will prepare you to pass the BCOP exam the first time. Each question comes with a concise rationale supporting the right answer or concept being tested.
Sample BCOP Question 1
When calculating power, the reduction in Beta (β) will likely result in what type of change to the sample size needed?
c. No change
d. Beta is not used in the calculation of Power
Correct Answer = a
Since Beta (β) by definition is the probability of a Type II error, then Power = 1-Beta is the probability of NOT making a Type II error. Note: the larger the Beta the lower the power of study and greater chance of making a Type II error. Therefore, the smaller the Beta the larger the power and less chance of making a type II error, results in the study that needs more patients or larger sample size in order to find a difference if it in fact does exist. Type II error occurs when a study states there is no difference between the groups assessed but in reality there is a difference. Any time a study fails to find a statistical difference between two groups the greater the chance that a Type II error has occurred.
Sample BCOP Question 2
CC is a 44 year old male recently diagnosed with
Burkitt's like lymphoma. Three days into receiving Hyper-CVAD therapy
(cyclophosphamide, vincristine, doxorubicin, dexamethasone), the nurses noted a
decrease urinary output plus the following labs were found: BUN 22 mg/dL,
serum creatinine 1.6 mg/dL, uric acid 14.5 mg/dL, phosphorous 4.4 mg/dL, and
potassium 4.6 mEq/L. Which agent should be started immediately to immediately lower the
uric acid level?
Correct answer: c
Allopurinol prevents the formation of uric acid so it does not have any influence on circulating uric acid. The only agent list that will have a significant impact on uric acid levels will be rasbuicase. Rasbuciase rapidly converts uric acid to allantoin which is readily eliminated renally. It should be considered when patients have an elevated uric acid plus an altered renal clearnace most likely to uric acid nephropathy. Probenecid prevents the reabsorption of uric acid at the proximal convoluted tubule which allows for renal elimination of excess uric acide; this drug is not used for elevated uric acid levels from tumor lysis syndrome
Sample BCOP Question 3
A 55 year old patient with Stage 2A
HER2 positive breast cancer receiving every three week adjuvant trastuzumab
therapy. At her appointment, she complains of fatigue and the inability
to do her normal daily activities. Her lab results show that she is
anemic with a hemoglobin of 9.9 g/dL (hematocrit 29%). Which of the following
treatments would be best for this patient?
a. Start epoetin alfa 40,000 units SQ weekly
b. Begin darbepoetin alfa 500 mcg SQ every three weeks
c. Initiate iron sucrose 200 mg IV followed by darbepoetin 500 mcg SQ every 3 weeks
d. No erythropoiesis stimulating agent (ESA) is indicated
Correct Answer = d
This patient does not qualify for
erythropoiesis stimulating agent (ESA) therapy for two main reasons that are
stated in the package insert. First she is an early stage breast cancer
patient so ESA use is not indicated in curative patients. Second she is
not receiving myelosuppressive chemotherapy. The use of monoclonal
antibodies such as trastuzumab (Herceptin) are not considered myelosuppressive
chemotherapy. Since ESAs have a small but significant risk of disease
recurrence and death, ESA use in curative patients is not recommended.
Sample BCOP Question 4
If a patient presents with CNS symptoms such as severe headaches or stroke-like symptoms from leukocytosis, which leukemia would they most likely have if treated with hydroxyrea, allopurinol, and leukopheresis?
d. Plasma cell leukemia
Correct answer: c
Patients with chronic myelogenous leukemia (CML) can present with white blood cell counts over 100,000 and the blood can develop leukostasis. The patient may exhibit stroke-like symptoms because of the lack of blood flow or embolus development from the viscous blood flow. Patients should undergo a procedure to remove the white blood cells called leukopheresis. Tumor lysis is a potential threat so allopurinol needs to initiated along with electrolyte management. The use of hydroxyurea is needed to rapidly reduce the leukemia burden.